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Abstract In most cases, acute diarrhoea will become self-
limiting during the first few days after onset. For young
children, however, health risks may develop when the
disease lasts longer than 3 days. The purpose of the present
trial was to determine whether the stool frequency of infants
and toddlers suffering from acute diarrhoea could be
normalised more quickly by administering the probiotic
Escherichia coli Nissle 1917 (EcN) solution than by
administering a placebo. The safety of EcN were also
assessed. A total of 113 children (aged 2–47 months) with
acute diarrhoea (> three watery or loose stools in 24 h) were
randomised to either a group receiving the probiotic EcN
suspension (n=55) or a group receiving the placebo
suspension (n=58) in a confirmative, double-blind clinical
trial. Depending on the age of patients, 1–3m lp e rd a yo f
verum suspension (10
8 viable EcN cells per millilitre) or
placebo were administered orally. The causes of the
diarrhoea were viral rather than bacterial, but they were
mainly unspecific infections. The median onset of treatment
response (reduction of daily stool frequency to ≤ three
watery or loose stools over at least 2 consecutive days)
occurred more rapidly in the children receiving the EcN
solution (2.5 days) than in those receiving the placebo
(4.8 days), a significant difference (2.3 days; p=0.0007). The
number of patients showing a response was clearly higher
(p<0.0001) in the EcN group (52/55; 94.5%) than in the
placebo group (39/58; 67.2%). EcN was found to be safe and
well-tolerated, and it showed a significant superiority
compared to the placebo in the treatment of acute diarrhoea
in infants and toddlers.
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Introduction
Probiotics are non-pathogenic microorganisms – mostly of
human origin – which confer health benefits to the host
when administered in adequate amounts. They are consid-
ered to be a safe and effective part of the first-line therapy
for acute diarrhoea in children and adults [12]. In addition,
probiotics are able to prevent or improve not only
gastrointestinal diseases such as inflammatory bowel
disease, irritable bowel syndrome, infectious gastroenteritis
or diverticular disease of the colon, but also to act in the
prevention of allergic diseases.
Various probiotics are commercially available in, for
example, Europe, the USA and Japan where they are
marketed as functional foods or probiotic drugs. To date,
lactobacilli, bifidobacteria and Saccharomyces boulardii are
the most commonly marketed probiotic active substances.
Certain strains of Escherichia coli are also available in
some European countries, the best known example of
which is E. coli strain Nissle 1917 (EcN).
EcN is marketed as a probiotic drug in two galenic
presentations for oral use: enteric-coated capsules and a
suspension in which 1 ml contains 10
8 viable EcN cells.
While capsules are mostly used in adults (e.g. Kruis et al.
[8]), the use of the suspension form is the most reasonable
form in neonates, infants and toddlers.
The purpose of the present trial was to examine the
efficacy and safety of an EcN suspension administered to
infants and toddlers suffering from acute diarrhoea of
different causes in terms of normalising the stool frequency.
Materials and methods
Infants and toddlers treated for acute diarrhoea in the
paediatric outpatient wards of 11 centres between February
and April 2005 were eligible for enrollment in this study.
This was a multicentre, prospective, confirmative, random-
ised, double-blind, placebo-controlled, parallel group clin-
ical trial of phase III. It was carried out in accordance with
the requirements of Good Clinical Practice and the Revised
Declaration of Helsinki. The study was approved by the
Independent Ethics Committee (IEC) of the Federal Agency
of Drugs Quality Control, Moscow, Russia, and by the IEC
of the State Enterprise Centre of Immunobiological Med-
icines at the Ministry of Health of Ukraine.
Acute diarrhoea was defined as more than three watery-
to-loose stools per day from an acute episode of non-bloody
diarrhoea which did not persist longer than 3 successive
days. For reasons of comparability, one of the exclusion
criteria was a higher grade of dehydration (loss of body
weight >5%; hydration status was surveyed, rehydration
was not implemented in low-grade dehydration); the most
important inclusion and exclusion criteria are listed in
Table 1. The participant was assessed until ascertainment of
response, 10 days at maximum. An overview of the study
design is presented in Fig. 1. A stool sample was taken at
both the beginning and end of the study and checked for the
presence of the following pathogens: Salmonella, Cam-
pylobacter, Yersinia, E. coli (ETEC, EPEC, EIEC, EHEC),
Shigella, Entamoeba histolytica, Cryptosporidium parvum
and Rota-, Adeno- and Noroviruses.
The parents were asked to maintain a daily record (diary)
containing information on the number of stools, stool
consistency, admixtures of blood or mucus, frequency of
vomiting, abdominal pain and cramps and fluid intake as
well as concomitant medication and general state of health.
An assessment of general health was also documented
during each control visit by the investigator and parents.
The randomisation schedule was generated by means of
SAS, ver. 9.1 (SAS Institute, Cary, N.C.) based on seed
valuesdependentonarandomnumbergenerator.Themethod
of randomly permuted blocks was used (block size: 4).
Study medication
The drug being studied (verum) is a commercially available
suspension for oral use that contains non-pathogenic E. coli
strain Nissle 1917 (Mutaflor suspension; Ardeypharm,
Herdecke, Germany, with 10
8 viable microorganisms per
millilitre). As placebo, we administered an identical
preparation consisting of a suspension devoid of the active
substance. In accordance with good clinical practice (GCP),
identical containers were used in order to guarantee a
concealed random allocation both to the parents and the
study personnel involved. Depending on the age, daily
doses of the study medication (EcN or placebo) were:
Infants <1 year 1 ml once daily
Toddlers ≥1t o≤3 years 1 ml twice daily
Toddlers >3 to <4 years 1 ml three times daily
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trial medication was documented. The investigator checked
the entries for completeness and plausibility. The compli-
ance was also evaluated by comparing the amount of trial
medication handed out with that returns.
Outcome
The primary effect criterion was the time to response.
Treatment response was defined as a reduction in stool
frequency to ≤ three watery or loose stools in 24 h over a
period of at least 2 consecutive days. Secondary effect
criteria included the response rate, stool consistency,
abdominal pain and cramps, body temperature, frequency
of vomiting, occurrence of adverse events and tolerance to
the study medication.
Statistical analysis
The study was conducted according to a three-stage group
sequential test design (O’Brien/Fleming type) with possible
sample size adaptation after the two planned interim
analyses [9]. A time-to-response analysis was performed
(Kaplan-Meier method; log-rank test to test the superiority
of EcN compared to placebo; overall type-I error rate
α=0.025; one-sided). The response rates were also com-
puted and compared between treatment groups by means of
Fisher’s exact test (one-sided; exploratory). The intention-
to-treat (ITT) data set included all randomised patients who
took at least one dose of study medication (primary
analysis), whereas patients with major protocol violations
were excluded from the per-protocol (PP) analysis. The
analysis sets were defined in a blind review of the data. The
sample size was estimated prospectively using ADDPLAN
ver. 3.0. An independent data monitoring committee
(IDMC) was responsible for reviewing the results of the
interim analyses and giving recommendations. Two interim
analyses were performed, resulting in continuation of the
study with the pre-planned sample sizes.
Results
Baseline data
A total of 113 infants and toddlers between 2 and 47 months
of age with acute diarrhoea were admitted to the trial. All
patients were Caucasian. The patients were randomly
allocated to either the EcN group (55 patients) or the
placebo group (58 patients) (Fig. 2). No relevant differ-
ences between the groups were observed in terms of
gender, age, height, weight and BMI of the patients
(Table 2). The vast majority of patients had an average
body development and a good nutritional status, but
reduced appetite was reported. There were also no differ-
ences in systolic and diastolic blood pressure, heart rate and
body temperature between the two treatment groups at
baseline.
Fig. 1 Study design. *Final
visit Duration of treatment,
which was until ascertainment
of response, 10 days at
maximum
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age <4 years at the time of enrolment Dehydration (>5% loss of body weight)
More than three watery or loose non-bloody stools in a 24-h period
that had not persisted for more than three consecutive days
Participation in another clinical trial
Signed informed consent by the parents Intake of EcN within the past 3 months prior to enrolment
Intake of food supplements or drugs which contain living microorganisms
or their metabolic products or components within 7 days prior to
enrolment or during the trial
Other antidiarrhoeal drugs
Antibiotics
Breast-feeding, Premature birth
Severe or chronic disease of the bowel or severe concomitant diseases
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acute diarrhoea episode between patients in the EcN group
and placebo group (EcN: 1.4±0.6 days, mean: 1.0 days;
placebo: 1.6±0.6 days, mean: 2.0 days). The number of
infections during the past 12 months was ≤ five in 55/55
patients (100%) of the EcN group and 56/58 patients
(96.6%) of the placebo group. Infections as a cause of the
acute diarrhoea were more often viral than bacterial.
However, unspecific infections were the most common
(Table 2). The number and proportion of patients with
pathogenic microorganisms were slightly higher in the EcN
group (27/55 patients) than in the placebo group (21/58
patients) at baseline. This difference was not statistically
significant.
Data analyses
All efficacy analyses were originally designed to be
performed on both the ITT and PP data sets. However, as
the ITTand PP data sets were identical in this study (n=113
patients), only the ITT data are evaluated here. All safety
analyses were performed on the ITT data set.
Primary objective
The median time to response was 2.5 days in the EcN
group and 4.8 days in the placebo group, i.e. treatment with
EcN shortened the duration of diarrhoea by 2.3 days.
Statistical testing revealed that the EcN treatment was
Table 2 Baseline data for the two treatment groups
EcN (n=55) Placebo (n=58)
Male gender 32 (58.2%) 32 (55.2%)
Age (median) 21 months 23 months
Height (median) 83 cm 83 cm
Weight (median) 12.7 kg 12.6 kg
BMI (median) 17.4 kg/m
2 17.2 kg/m
2
Mean duration of diarrhoea 1.4 days 1.6 days
Mean stool frequency 5.0 per day 5.1 per day
Possible causes for the current acute diarrhoea episode Previous antibiotic treatment 2 (3.6%) 4 (6.9%)
Virus infections 16 (29.1%) 19 (32.8%)
Bacterial infections 9 (16.4%) 4 (6.8%)
Unspecified infections 25 (45.5%) 29 (50.0%)
Other causes 3 (5.5%) 2 (3.4%)
Fig. 2 Diagram of participant flow
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to response (p=0.0007; overall p value of the group
sequential test design) (Fig. 3). Analysis by centre showed
no difference in the number of responders between
treatment groups.
In total, diarrhoea was stopped in 52/55 patients (94.5%)
in the EcN group and 39/58 patients (67.2%) in the placebo
group within 10 days. Fourteen patients dropped out of the
trials (EcN, n=1; placebo, n=13) because of unsuccessful
therapy. The diarrhoea did not cease within 10 days of
treatment in two patients of the EcN and six patients of the
placebo group.
Secondary objectives
An exploratory comparison showed a significant difference
in the number of responders between the treatment groups
(p<0.0001; ratio of rates: 1.406; 95%CI: 1.162–1.701). A
cumulative presentation of the number of responders on
each study day showed a difference between EcN- and
placebo-treated patients starting on day 3 [EcN 34/55
(61.8%) vs. placebo 24/58 (41.4%); ratio of rates: 1.494;
95%CI: 1.032–2.163] (Fig. 4). The difference increased
until day 5 [EcN 45/55 (81.8%) vs. placebo 30/58 (51.7%);
ratio of rates: 1.582; 95%CI: 1.198–2.089] and then
decreased slightly from day 6 to the end of study [EcN
52/55 (94.5%) vs. placebo 39/58 (67.2%); ratio of rates:
1.406; 95%CI: 1.162–1.701).
Prior to the treatment regimen, almost no infant had a
normal stool consistency. During the course of the study the
patients of the EcN group showed a more pronounced
improvement than their counterparts in the placebo group.
The same trend was observed for the disappearance of
abdominal pain (28/30 EcN patients vs. 24/33 placebo
patients) and abdominal cramps (17/18 EcN patients vs.
21/26 placebo patients) (Table 3).
Fig. 4 Response rates among
the patients receiving the EcN
solution (n=55) and placebo
(n=58) during the course of
the study
Fig. 3 Time-to-response curves:
Kaplan-Meier analysis
(ITT analysis)
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investigator during clinical examinations or by the parents
by means of the diary, of the patients in the EcN group
improved more clearly than that of the patients in the
placebo group (data not shown). Body temperature showed
an almost identical decrease over time in both treatment
groups (EcN: −0.5±0.4°C; placebo: −0.4±0.5°C). The
number of vomiting episodes was very small at baseline
in all patients and decreased to 0% in both groups. In
principle, body weight and the status of dehydration did not
show any changes from baseline to the end of study in
either treatment group. Only one patient in the placebo
group experienced mild dehydration.
From baseline to study termination, pathogenic micro-
organisms disappeared in a similar number of patients in both
treatment groups (14/27 patients in the EcN group and 12/21
patients in the placebo group). In the patients who were free
frominfectiousagentsatbaseline,pathogenicmicroorganisms
were detected at the end of study in 3/28 and 6/37 patients in
the EcN and placebo group, respectively.
Tolerance to treatment
The study medication was well tolerated. Only 2/55 patients
(3.6%) in the EcN group and 2/58 patients (3.4%) in the
placebo group experienced one adverse event (AE) each.
These were rhinitis and abdominal pain in the EcN-treated
patients and two cases of acute otitis media in the patients
receiving the placebo. According to the European Medicines
Agency (EMEA) classification, none of these AEs are rated
as “serious” or “severe” (regulatory guidance CPMP/ICH/
377/95). The two placebo-treated patients with otitis media
were removed from the study due to the AE being
intolerable. For the two AEs in patients receiving the EcN
treatment, complete recoverywas documented. According to
the parents, tolerance to treatment was slightly better in the
EcN group than in the placebo group, whereas no notable
difference was observed by the investigators (Table 4).
Discussion
The aim of this multicentre, prospective, confirmative,
randomised, double-blind, placebo-controlled clinical trial
of phase III was to investigate the therapeutic efficacy and
safety of orally administered EcN in treating acute
diarrhoea in infants and toddlers. The results showed that
EcN was superior to the placebo in terms of both time to
response and response rate. The difference in median
duration of diarrhoea – 2.3 days – was statistically
significant and also clinically important.
Acute diarrhoea in children is very often self-limiting
within a few days. However, toddlers and young infants are in
danger of developing dehydration and a deteriorating general
health. Therefore, a fast-tracking antidiarrhoeal treatment
would be beneficial. Several investigations have been carried
out with probiotics for the treatment of acute gastroenteritis,
and different meta-analyses and systematic reviews have been
published in this field. All of these have demonstrated the
efficacy of probiotics in treating or preventing diarrhoea. On
average, the treatment of diarrhoea with lactobacilli, bifido-
bacteria and/or S. boulardii shortened the duration of
diarrhoea by only 0.5–1.5 days [4, 12, 14, 18, 19].
Szajewska and Mrukowicz reviewed ten randomised,
double-blind, placebo-controlled studies and concluded that
the administration of probiotics led to a substantial
reduction in the duration of acute diarrhoeal symptoms: an
average of 20 h [18]. Moreover, a meta-analysis of nine
clinical trials conducted by D’Souza et al. demonstrated
that probiotics effectively prevented antibiotic-associated
diarrhoea [4]. The work of van Niel et al. included nine
randomised controlled studies with lactobacilli in acute
infectious diarrhoea in children. In these studies, the
duration of diarrhoea was significantly reduced by an
average of 0.7 days along with the stool frequency [19].
Most recently, McFarland et al. examined the efficacy of
probiotics in paediatric diarrhoea by analysing 39 random-
ised, controlled and blinded clinical trials comprising a total
of 41 probiotic treatment arms [12]. Of these, 32 (78%)
reported efficacy. The latest meta-analysis of 39 trials by
Sazawal et al. showed that probiotics prevented acute
diarrhea, with a risk reduction among children off 57%
(range: 35–71%) [14]. Diarrhoea is one of the best-studied
indications for probiotics, and treatment with EcN has
been found to stop acute diarrhoea more rapidly than
Table 4 Tolerance to treat-
ment in the two treatment
groups
aPercentage is given in
parenthesis
Assessed by parents Assessed by investigators
EcN Placebo EcN Placebo
Very good 11/55 (20.0)
a 4/58 (6.9) 5/55 (9.1) 4/58 (6.9)
Good 44/55 (80.0) 53/58 (91.4) 50/55 (90.9) 53/58 (91.4)
Poor 0/55 (0.0) 1/58 (1.7) 0/55 (0.0) 1/58 (1.7)
Table 3 Improvement of symptoms after treatment
EcN (%) Placebo (%)
Normal stool consistency 78.4 40.5
No abdominal pain 93.3 72.7
No abdominal cramps 94.4 80.8
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second multicentre, prospective, randomised, double-blind,
placebo-controlled phase III study conducted by our group
[7]. In that study, children with prolonged diarrhoea treated
with EcN showed a more rapid onset of response to
treatment than those treated with placebo (median: 2.4 vs.
5.7 days; p<0.0001). There was also a remarkable
difference in the response rates, as determined on days 14
(EcN: 93.3%; placebo: 65.8%) and 21 (EcN: 98.7%;
placebo: 71.1%), thus showing a statistically significant
superiority of EcN on both days (p=0.0017 and p<0.001,
respectively).
In the present trial, high initial response rates in both
groups represent the spontaneous healing known for acute
gastroenteritis. The superiority of the EcN treatment
became increasingly noticeable from 3. The healing process
was markedly faster in the EcN-treated patients than in the
patients receiving placebo, a result which underlines the
high efficacy of this probiotic.
The relatively high number of children with unspecific
diarrhoea corresponds quite well to the frequent failure to
detect the responsible pathogen in routine analyses. This is
the reason why the results of this study are not helpful in
answering the question whether EcN is more efficient in
bacterial or viral diarrhea. This question should be
addressed by future studies.
In the present study, EcN was safe and well-tolerated.
There was no difference between the EcN and placebo
treatments in terms of AEs, body weight, stool examina-
tions and the assessment of tolerance. This result is in
accordance with experience from clinical trials in premature
and fullterm newborns where EcN was not only very safe
but improved the microbial intestinal milieu of the treated
infants and reduced the risk of acquiring pathogens early in
life [3, 10, 11]. It has also been shown that prolonged
colonisation with EcN protected infants at an age of 6–
12 months from flatulence, diarrhoea or constipation when
given immediately on the first 5 days after birth [16].
Our understanding of the effects of probiotics and their
numerous modes of action has grown substantially in recent
years. With regard to gastroenteritis, probiotics may
improve symptoms by several mechanisms, including:
– competition with pathogens (for adherence to intestinal
epithelium, for growth and survival in the gut) and
inhibition of pathogen overgrowth;
– secretion of bacteriostatic/bactericidal peptides (e.g.
colicins, microcins);
– enforcement of intestinal barrier function and reduction
of microbial translocation;
– modulation of immune responses (local and/or system-
ic, e.g. stimulation of secretion of IgA by lymphocytes
and defensins by enterocytes).
All of these mechanisms of action have been shown for
E. coli strain Nissle 1917. The antagonistic activity of EcN
against pathogens has been demonstrated in vitro in animal
models and in humans [1, 10, 13, 17]. In a pig model of
intestinal infection, EcN was able to prevent acute secretory
diarrhoea [15]. Among many other strain-specific character-
istics [2, 5, 6], EcN exerts an intense immunomodulatory
effect in children [3, 11]. Here, EcN was found to stimulate
the production of antibodies of mucosa-associated B
lymphocytes and the systemic production of antibodies
(IgM, IgA) in premature and fullterm children.
Conclusion
In summary, EcN showed a significant superiority to
placebo in the treatment of acute diarrhoea in infants and
toddlers. EcN treatment also improved the general state
of health and its administration was safe and well
tolerated.
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